Biotech Companies Step Up Efforts in Biomass R&D

Business Editors & Health/Medical Writers  
BIOWIRE2K  
SAN DIEGO--(BW HealthWire)--June 26, 2001---Biotech companies are 
increasing their research on the use of biomass as alternative fuels 
in light of rising energy costs and increasing power outages, 
according to experts meeting at the Biotechnology Industry 
Organization's annual conference, being held this week in San Diego. 
Biomass research is also being explored as a source of other bio-based 
products.  
"Recent increases in gasoline, home heating oil, and natural gas 
prices have made everyone aware of how critical it is for us to 
develop new sources of energy," said Brent Erickson, director of BIO's 
environmental and biotechnology section. "BIO member companies are 
using genetic research to produce enzymes that will convert abundant 
agricultural biomass into fuels and plastics."  
Biomass efforts are being spurred on by U.S. government support at 
both the presidential and congressional levels. Congress has allocated 
$250 million over five years to establish an interagency research and 
development program to use biomass to produce energy, transportation 
fuels, and other products. Last year, then President Clinton signed 
the National Sustainable Fuels and Chemical Act. Through 2005, $49 
million will be allocated annually to explore applications of biomass 
as an alternative energy source.  
"The pharmaceutical and agricultural sectors of the biotechnology 
industry get most of the attention in the trade and consumer press, 
and rightfully so," notes John Sterling, managing editor of Genetic 
Engineering News (GEN; www.genengnews.com). "But the recent energy 
crises in California and elsewhere have highlighted the need for 
cheaper and less polluting forms of fuel. Biotechnology is tackling 
this problem head-on."  
Among the key players in the race to turn biomass into useful 
products are Genencor (NASDAQ:GCOR), Diversa (NASDAQ:DVSA), Protein 
Polymer Technologies (OTCBB:PPTI), Eastman Chemical Co. (NYSE:EMN), 
Novozymes Biotech (an R&D subsidiary of Novozymes A/S; U.S. 
OTC:NVZMF), and Cargill Dow (a 50-50 joint venture of Dow Chemical 
(NYSE:DOW) and Cargill Inc. (private)). 
 
 
Press spacebar to pause and continue. Press esc to stop.